Skip to main content
2026 AAOMS 108th Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticketed <br><i>This session/event requires a ticket.</i>
Ticketed
This session/event requires a ticket.
In-person only<br><i>This session is offered in-person only.</i>
In-person only
This session is offered in-person only.
On-demand<br><i>On-demand session available beginning Sept. 28.</i>
On-demand
On-demand session available beginning Sept. 28.
Recorded<br><i>This session will be recorded and available beginning Oct. 19</i>
Recorded
This session will be recorded and available beginning Oct. 19
Sold Out<br><i>This ticketed session/event is sold out.</i>
Sold Out
This ticketed session/event is sold out.

Pathology

OMS and Other Dental Specialists

Residents

SSOD39 - Pharmacology Meets Pathology: Navigating MRONJ in Surgical Practice

On-demand
CE: 1.0 CDE/CME
On-demand<br><i>On-demand session available beginning Sept. 28.</i>
This session will provide oral and maxillofacial surgeons with a focused overview of the pharmacology of antiresorptive drugs - primarily bisphosphonates and denosumab - and their association with medication-related osteonecrosis of the jaw (MRONJ). The session will explore mechanisms of action, therapeutic indications and pharmacokinetics of these agents, emphasizing how they alter bone remodeling and contribute to MRONJ pathogenesis. Attendees will learn to identify high-risk patients, understand staging criteria and apply evidence-based prevention and management strategies. The presentation also will address emerging therapies and evolving guidelines, including updates from the AAOMS 2022 position paper, ADA clinical recommendations and recent literature reviews. By enhancing pharmacologic understanding and clinical vigilance, OMS professionals can improve patient outcomes and reduce the incidence of MRONJ in both oncologic and osteoporotic populations.

Learning Objectives:

At the conclusion of this presentation, participants should be able to:
  1. Describe the pharmacologic mechanisms and clinical indications of antiresorptive agents such as bisphosphonates and denosumab and their role in bone metabolism.
  2. Identify patient risk factors and clinical presentations associated with medication-related osteonecrosis of the jaw (MRONJ) and specific drugs to support early diagnosis and prevention.
  3. Apply evidence-based strategies for the management and prevention of MRONJ with a greater understanding of pharmacology in patients undergoing oral and maxillofacial surgical procedures.